{"entity":{"id":"nct04271644","kind":"trial","name":"BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease","aka":[],"tldr":"A phase 1/2 trial of BCMA CAR-T cells in multiple myeloma, run by Chongqing Precision Biotech Co., Ltd, now recruiting.","summary":"BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease is a phase 1/2 interventional study registered as NCT04271644 by Chongqing Precision Biotech Co., Ltd, with 80 participants planned, started 2019-04-01 and due to reach its primary completion in 2026-12-31. Interventions recorded: BCMA CAR-T cells.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04271644","url":"https://clinicaltrials.gov/study/NCT04271644"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["chongqing-precision-biotech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04271644","phase":"1/2","setting":"BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease","sponsor":"Chongqing Precision Biotech Co., Ltd","enrolled":80,"outcomes":[]},"route":"/trials/nct04271644/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"company":[{"id":"chongqing-precision-biotech","kind":"company","name":"Chongqing Precision Biotech","route":"/companies/chongqing-precision-biotech/"}]}}